SARS-CoV-2: fear versus data
Identifieur interne : 001066 ( Pmc/Corpus ); précédent : 001065; suivant : 001067SARS-CoV-2: fear versus data
Auteurs : Yanis Roussel ; Audrey Giraud-Gatineau ; Marie-Thérèse Jimeno ; Jean-Marc Rolain ; Christine Zandotti ; Philippe Colson ; Didier RaoultSource :
- International Journal of Antimicrobial Agents [ 0924-8579 ] ; 2020.
Abstract
Comparison of incidence and mortality rates of four common coronaviruses circulating in France with those of SARS-CoV-2 in OECD countries. As of 2 March 2020, 90 307 patients had tested positive for SARS-CoV-2 worldwide, with 3086 deaths (mortality rate 3.4%). As of 2 March 2020, among OECD countries, 7476 patients had tested positive for SARS-CoV-2, with 96 deaths (mortality rate 1.3%) As of 2 March 2020, in France, 191 people had tested positive for SARS-CoV-2, with three deaths (mortality rate 1.6%). In OECD countries. the mortality rate for SARS-CoV-2 (1.3%) is not significantly different from that for common coronaviruses identified in public hospitals of Marseille, France (0.8%; The problem of SARS-CoV-2 is probably overestimated, as 2.6 million people die of respiratory infections each year compared with less than 4000 deaths for SARS-CoV-2 at the time of writing.
Url:
DOI: 10.1016/j.ijantimicag.2020.105947
PubMed: 32201354
PubMed Central: 7102597
Links to Exploration step
PMC:7102597Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS-CoV-2: fear versus data</title><author><name sortKey="Roussel, Yanis" sort="Roussel, Yanis" uniqKey="Roussel Y" first="Yanis" last="Roussel">Yanis Roussel</name><affiliation><nlm:aff id="aff0001">Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff0002">Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Microbes Evolution Phylogénie et Infections, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Giraud Gatineau, Audrey" sort="Giraud Gatineau, Audrey" uniqKey="Giraud Gatineau A" first="Audrey" last="Giraud-Gatineau">Audrey Giraud-Gatineau</name><affiliation><nlm:aff id="aff0001">Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff0003">Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Service de Santé des Armées, Vecteurs - Infections Tropicales et Méditerranéennes, Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff0004">Centre d'Epidémiologie et de Santé Publique des Armées, Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff0005">Assistance Publique – Hôpitaux de Marseille, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Jimeno, Marie Therese" sort="Jimeno, Marie Therese" uniqKey="Jimeno M" first="Marie-Thérèse" last="Jimeno">Marie-Thérèse Jimeno</name><affiliation><nlm:aff id="aff0005">Assistance Publique – Hôpitaux de Marseille, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Rolain, Jean Marc" sort="Rolain, Jean Marc" uniqKey="Rolain J" first="Jean-Marc" last="Rolain">Jean-Marc Rolain</name><affiliation><nlm:aff id="aff0001">Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff0002">Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Microbes Evolution Phylogénie et Infections, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Zandotti, Christine" sort="Zandotti, Christine" uniqKey="Zandotti C" first="Christine" last="Zandotti">Christine Zandotti</name><affiliation><nlm:aff id="aff0001">Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff0002">Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Microbes Evolution Phylogénie et Infections, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Colson, Philippe" sort="Colson, Philippe" uniqKey="Colson P" first="Philippe" last="Colson">Philippe Colson</name><affiliation><nlm:aff id="aff0001">Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff0002">Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Microbes Evolution Phylogénie et Infections, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Raoult, Didier" sort="Raoult, Didier" uniqKey="Raoult D" first="Didier" last="Raoult">Didier Raoult</name><affiliation><nlm:aff id="aff0001">Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff0002">Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Microbes Evolution Phylogénie et Infections, Marseille, France</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">32201354</idno><idno type="pmc">7102597</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102597</idno><idno type="RBID">PMC:7102597</idno><idno type="doi">10.1016/j.ijantimicag.2020.105947</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">001066</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001066</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">SARS-CoV-2: fear versus data</title><author><name sortKey="Roussel, Yanis" sort="Roussel, Yanis" uniqKey="Roussel Y" first="Yanis" last="Roussel">Yanis Roussel</name><affiliation><nlm:aff id="aff0001">Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff0002">Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Microbes Evolution Phylogénie et Infections, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Giraud Gatineau, Audrey" sort="Giraud Gatineau, Audrey" uniqKey="Giraud Gatineau A" first="Audrey" last="Giraud-Gatineau">Audrey Giraud-Gatineau</name><affiliation><nlm:aff id="aff0001">Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff0003">Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Service de Santé des Armées, Vecteurs - Infections Tropicales et Méditerranéennes, Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff0004">Centre d'Epidémiologie et de Santé Publique des Armées, Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff0005">Assistance Publique – Hôpitaux de Marseille, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Jimeno, Marie Therese" sort="Jimeno, Marie Therese" uniqKey="Jimeno M" first="Marie-Thérèse" last="Jimeno">Marie-Thérèse Jimeno</name><affiliation><nlm:aff id="aff0005">Assistance Publique – Hôpitaux de Marseille, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Rolain, Jean Marc" sort="Rolain, Jean Marc" uniqKey="Rolain J" first="Jean-Marc" last="Rolain">Jean-Marc Rolain</name><affiliation><nlm:aff id="aff0001">Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff0002">Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Microbes Evolution Phylogénie et Infections, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Zandotti, Christine" sort="Zandotti, Christine" uniqKey="Zandotti C" first="Christine" last="Zandotti">Christine Zandotti</name><affiliation><nlm:aff id="aff0001">Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff0002">Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Microbes Evolution Phylogénie et Infections, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Colson, Philippe" sort="Colson, Philippe" uniqKey="Colson P" first="Philippe" last="Colson">Philippe Colson</name><affiliation><nlm:aff id="aff0001">Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff0002">Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Microbes Evolution Phylogénie et Infections, Marseille, France</nlm:aff></affiliation></author><author><name sortKey="Raoult, Didier" sort="Raoult, Didier" uniqKey="Raoult D" first="Didier" last="Raoult">Didier Raoult</name><affiliation><nlm:aff id="aff0001">Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff0002">Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Microbes Evolution Phylogénie et Infections, Marseille, France</nlm:aff></affiliation></author></analytic><series><title level="j">International Journal of Antimicrobial Agents</title><idno type="ISSN">0924-8579</idno><idno type="eISSN">1872-7913</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Highlights</title><p><list list-type="simple" id="celist0001"><list-item id="celistitem0001"><label>•</label><p id="para0001">Comparison of incidence and mortality rates of four common coronaviruses circulating in France with those of SARS-CoV-2 in OECD countries.</p></list-item><list-item id="celistitem0002"><label>•</label><p id="para0002">As of 2 March 2020, 90 307 patients had tested positive for SARS-CoV-2 worldwide, with 3086 deaths (mortality rate 3.4%).</p></list-item><list-item id="celistitem0003"><label>•</label><p id="para0003">As of 2 March 2020, among OECD countries, 7476 patients had tested positive for SARS-CoV-2, with 96 deaths (mortality rate 1.3%)</p></list-item><list-item id="celistitem0004"><label>•</label><p id="para0004">As of 2 March 2020, in France, 191 people had tested positive for SARS-CoV-2, with three deaths (mortality rate 1.6%).</p></list-item><list-item id="celistitem0005"><label>•</label><p id="para0005">In OECD countries. the mortality rate for SARS-CoV-2 (1.3%) is not significantly different from that for common coronaviruses identified in public hospitals of Marseille, France (0.8%; <italic>P</italic>=0.11).</p></list-item><list-item id="celistitem0006"><label>•</label><p id="para0006">The problem of SARS-CoV-2 is probably overestimated, as 2.6 million people die of respiratory infections each year compared with less than 4000 deaths for SARS-CoV-2 at the time of writing.</p></list-item></list></p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="To, K K" uniqKey="To K">K.K. To</name></author><author><name sortKey="Hung, I F" uniqKey="Hung I">I.F. Hung</name></author><author><name sortKey="Chan, J F" uniqKey="Chan J">J.F. Chan</name></author><author><name sortKey="Yuen, K Y" uniqKey="Yuen K">K.Y. Yuen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wu, Z" uniqKey="Wu Z">Z. Wu</name></author><author><name sortKey="Mcgoogan, J M" uniqKey="Mcgoogan J">J.M. McGoogan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Le Viet, N" uniqKey="Le Viet N">N. Le-Viet</name></author><author><name sortKey="Le, V N" uniqKey="Le V">V.N. Le</name></author><author><name sortKey="Chung, H" uniqKey="Chung H">H. Chung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hand, J" uniqKey="Hand J">J. Hand</name></author><author><name sortKey="Rose, E B" uniqKey="Rose E">E.B. Rose</name></author><author><name sortKey="Salinas, A" uniqKey="Salinas A">A. Salinas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vandroux, D" uniqKey="Vandroux D">D. Vandroux</name></author><author><name sortKey="Allou, N" uniqKey="Allou N">N. Allou</name></author><author><name sortKey="Jabot, J" uniqKey="Jabot J">J. Jabot</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kanwar, A" uniqKey="Kanwar A">A. Kanwar</name></author><author><name sortKey="Selvaraju, S" uniqKey="Selvaraju S">S. Selvaraju</name></author><author><name sortKey="Esper, F" uniqKey="Esper F">F. Esper</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Trombetta, H" uniqKey="Trombetta H">H. Trombetta</name></author><author><name sortKey="Faggion, H Z" uniqKey="Faggion H">H.Z. Faggion</name></author><author><name sortKey="Leotte, J" uniqKey="Leotte J">J. Leotte</name></author><author><name sortKey="Nogueira, M B" uniqKey="Nogueira M">M.B. Nogueira</name></author><author><name sortKey="Vidal, L R" uniqKey="Vidal L">L.R. Vidal</name></author><author><name sortKey="Raboni, S M" uniqKey="Raboni S">S.M. Raboni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lau, S K" uniqKey="Lau S">S.K. Lau</name></author><author><name sortKey="Woo, P C" uniqKey="Woo P">P.C. Woo</name></author><author><name sortKey="Yip, C C" uniqKey="Yip C">C.C. Yip</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Owusu, M" uniqKey="Owusu M">M. Owusu</name></author><author><name sortKey="Annan, A" uniqKey="Annan A">A. Annan</name></author><author><name sortKey="Corman, V M" uniqKey="Corman V">V.M. Corman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, S F" uniqKey="Zhang S">S.F. Zhang</name></author><author><name sortKey="Tuo, J L" uniqKey="Tuo J">J.L. Tuo</name></author><author><name sortKey="Huang, X B" uniqKey="Huang X">X.B. Huang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zeng, Z Q" uniqKey="Zeng Z">Z.Q. Zeng</name></author><author><name sortKey="Chen, D H" uniqKey="Chen D">D.H. Chen</name></author><author><name sortKey="Tan, W P" uniqKey="Tan W">W.P. Tan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sipulwa, L A" uniqKey="Sipulwa L">L.A. Sipulwa</name></author><author><name sortKey="Ongus, J R" uniqKey="Ongus J">J.R. Ongus</name></author><author><name sortKey="Coldren, R L" uniqKey="Coldren R">R.L. Coldren</name></author><author><name sortKey="Bulimo, W D" uniqKey="Bulimo W">W.D. Bulimo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kiyuka, P K" uniqKey="Kiyuka P">P.K. Kiyuka</name></author><author><name sortKey="Agoti, C N" uniqKey="Agoti C">C.N. Agoti</name></author><author><name sortKey="Munywoki, P K" uniqKey="Munywoki P">P.K. Munywoki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Killerby, M E" uniqKey="Killerby M">M.E. Killerby</name></author><author><name sortKey="Biggs, H M" uniqKey="Biggs H">H.M. Biggs</name></author><author><name sortKey="Haynes, A" uniqKey="Haynes A">A. Haynes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peiris, J S" uniqKey="Peiris J">J.S. Peiris</name></author><author><name sortKey="Yuen, K Y" uniqKey="Yuen K">K.Y. Yuen</name></author><author><name sortKey="Osterhaus, A D" uniqKey="Osterhaus A">A.D. Osterhaus</name></author><author><name sortKey="Stohr, K" uniqKey="Stohr K">K. Stöhr</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Wit, E" uniqKey="De Wit E">E. de Wit</name></author><author><name sortKey="Van Doremalen, N" uniqKey="Van Doremalen N">N. van Doremalen</name></author><author><name sortKey="Falzarano, D" uniqKey="Falzarano D">D. Falzarano</name></author><author><name sortKey="Munster, V J" uniqKey="Munster V">V.J. Munster</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zaki, A M" uniqKey="Zaki A">A.M. Zaki</name></author><author><name sortKey="Van Boheemen, S" uniqKey="Van Boheemen S">S. van Boheemen</name></author><author><name sortKey="Bestebroer, T M" uniqKey="Bestebroer T">T.M. Bestebroer</name></author><author><name sortKey="Osterhaus, A D" uniqKey="Osterhaus A">A.D. Osterhaus</name></author><author><name sortKey="Fouchier, R A" uniqKey="Fouchier R">R.A. Fouchier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hui, D S" uniqKey="Hui D">D.S. Hui</name></author><author><name sortKey="Azhar, E I" uniqKey="Azhar E">E.I. Azhar</name></author><author><name sortKey="Kim, Y J" uniqKey="Kim Y">Y.J. Kim</name></author><author><name sortKey="Memish, Z A" uniqKey="Memish Z">Z.A. Memish</name></author><author><name sortKey="Oh, M D" uniqKey="Oh M">M.D. Oh</name></author><author><name sortKey="Zumla, A" uniqKey="Zumla A">A. Zumla</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Rocklov, J" uniqKey="Rocklov J">J. Rocklöv</name></author><author><name sortKey="Sjodin, H" uniqKey="Sjodin H">H. Sjödin</name></author><author><name sortKey="Wilder Smith, A" uniqKey="Wilder Smith A">A. Wilder-Smith</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gagneur, A" uniqKey="Gagneur A">A. Gagneur</name></author><author><name sortKey="Vallet, S" uniqKey="Vallet S">S. Vallet</name></author><author><name sortKey="Talbot, P J" uniqKey="Talbot P">P.J. Talbot</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Abat, C" uniqKey="Abat C">C. Abat</name></author><author><name sortKey="Chaudet, H" uniqKey="Chaudet H">H. Chaudet</name></author><author><name sortKey="Colson, P" uniqKey="Colson P">P. Colson</name></author><author><name sortKey="Rolain, J M" uniqKey="Rolain J">J.M. Rolain</name></author><author><name sortKey="Raoult, D" uniqKey="Raoult D">D. Raoult</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Edouard, S" uniqKey="Edouard S">S. Edouard</name></author><author><name sortKey="Million, M" uniqKey="Million M">M. Million</name></author><author><name sortKey="Bachar, D" uniqKey="Bachar D">D. Bachar</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Goyal, K" uniqKey="Goyal K">K. Goyal</name></author><author><name sortKey="Chauhan, P" uniqKey="Chauhan P">P. Chauhan</name></author><author><name sortKey="Chhikara, K" uniqKey="Chhikara K">K. Chhikara</name></author><author><name sortKey="Gupta, P" uniqKey="Gupta P">P. Gupta</name></author><author><name sortKey="Singh, M P" uniqKey="Singh M">M.P. Singh</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Dube, F S" uniqKey="Dube F">F.S. Dube</name></author><author><name sortKey="Kaba, M" uniqKey="Kaba M">M. Kaba</name></author><author><name sortKey="Robberts, F J" uniqKey="Robberts F">F.J. Robberts</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="K, Subramoney" uniqKey="K S">Subramoney K.</name></author><author><name sortKey="O, Hellferscee" uniqKey="O H">Hellferscee O.</name></author><author><name sortKey="M, Pretorius" uniqKey="M P">Pretorius M.</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nunes, M C" uniqKey="Nunes M">M.C. Nunes</name></author><author><name sortKey="Kuschner, Z" uniqKey="Kuschner Z">Z. Kuschner</name></author><author><name sortKey="Rabede, Z" uniqKey="Rabede Z">Z. Rabede</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Antimicrob Agents</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Antimicrob. Agents</journal-id><journal-title-group><journal-title>International Journal of Antimicrobial Agents</journal-title></journal-title-group><issn pub-type="ppub">0924-8579</issn><issn pub-type="epub">1872-7913</issn><publisher><publisher-name>Elsevier B.V. and International Society of Chemotherapy.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32201354</article-id><article-id pub-id-type="pmc">7102597</article-id><article-id pub-id-type="publisher-id">S0924-8579(20)30097-2</article-id><article-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105947</article-id><article-id pub-id-type="publisher-id">105947</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>SARS-CoV-2: fear versus data</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name><surname>Roussel</surname><given-names>Yanis</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0002"><name><surname>Giraud-Gatineau</surname><given-names>Audrey</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0003" ref-type="aff">c</xref><xref rid="aff0004" ref-type="aff">d</xref><xref rid="aff0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0003"><name><surname>Jimeno</surname><given-names>Marie-Thérèse</given-names></name><xref rid="aff0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0004"><name><surname>Rolain</surname><given-names>Jean-Marc</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0005"><name><surname>Zandotti</surname><given-names>Christine</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0006"><name><surname>Colson</surname><given-names>Philippe</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0007"><name><surname>Raoult</surname><given-names>Didier</given-names></name><email>didier.raoult@gmail.com</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref><xref rid="cor0001" ref-type="corresp">⁎</xref></contrib></contrib-group><aff id="aff0001"><label>a</label>Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France</aff><aff id="aff0002"><label>b</label>Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Microbes Evolution Phylogénie et Infections, Marseille, France</aff><aff id="aff0003"><label>c</label>Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Service de Santé des Armées, Vecteurs - Infections Tropicales et Méditerranéennes, Marseille, France</aff><aff id="aff0004"><label>d</label>Centre d'Epidémiologie et de Santé Publique des Armées, Marseille, France</aff><aff id="aff0005"><label>e</label>Assistance Publique – Hôpitaux de Marseille, Marseille, France</aff><author-notes><corresp id="cor0001"><label>⁎</label>Corresponding author. Address: IHU Méditerranée Infection, Faculté de Médecine, Aix-Marseille Université, 27 Boulevard Jean Moulin, 13385 Marseille, CEDEX 5, France. Tel.: +33 (0)4 91 32 43 75; fax: + 33 (0)4 91 38 77 72. <email>didier.raoult@gmail.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>19</day><month>3</month><year>2020</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="epub"><day>19</day><month>3</month><year>2020</year></pub-date><elocation-id>105947</elocation-id><permissions><copyright-statement>© 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="author-highlights" id="abs0001"><title>Highlights</title><p><list list-type="simple" id="celist0001"><list-item id="celistitem0001"><label>•</label><p id="para0001">Comparison of incidence and mortality rates of four common coronaviruses circulating in France with those of SARS-CoV-2 in OECD countries.</p></list-item><list-item id="celistitem0002"><label>•</label><p id="para0002">As of 2 March 2020, 90 307 patients had tested positive for SARS-CoV-2 worldwide, with 3086 deaths (mortality rate 3.4%).</p></list-item><list-item id="celistitem0003"><label>•</label><p id="para0003">As of 2 March 2020, among OECD countries, 7476 patients had tested positive for SARS-CoV-2, with 96 deaths (mortality rate 1.3%)</p></list-item><list-item id="celistitem0004"><label>•</label><p id="para0004">As of 2 March 2020, in France, 191 people had tested positive for SARS-CoV-2, with three deaths (mortality rate 1.6%).</p></list-item><list-item id="celistitem0005"><label>•</label><p id="para0005">In OECD countries. the mortality rate for SARS-CoV-2 (1.3%) is not significantly different from that for common coronaviruses identified in public hospitals of Marseille, France (0.8%; <italic>P</italic>=0.11).</p></list-item><list-item id="celistitem0006"><label>•</label><p id="para0006">The problem of SARS-CoV-2 is probably overestimated, as 2.6 million people die of respiratory infections each year compared with less than 4000 deaths for SARS-CoV-2 at the time of writing.</p></list-item></list></p></abstract><abstract id="abs0002"><p>SARS-CoV-2, the novel coronavirus from China, is spreading around the world, causing a huge reaction despite its current low incidence outside China and the Far East. Four common coronaviruses are in current circulation and cause millions of cases worldwide. This article compares the incidence and mortality rates of these four common coronaviruses with those of SARS-CoV-2 in Organisation for Economic Co-operation and Development countries. It is concluded that the problem of SARS-CoV-2 is probably being overestimated, as 2.6 million people die of respiratory infections each year compared with less than 4000 deaths for SARS-CoV-2 at the time of writing.</p></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>COVID-19</kwd><kwd>Coronavirus</kwd><kwd>SARS-CoV-2</kwd></kwd-group></article-meta><notes><p id="mis0001">Dr. Po-Ren Hsueh</p></notes></front><body><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0007">Coronaviridae represent a very important family of animal and human viruses <xref rid="bib0001" ref-type="bibr">[1</xref>,<xref rid="bib0002" ref-type="bibr">2]</xref> that are in permanent circulation. Four common human coronaviruses (HKU1, NL63, OC43 and E229) cause 10–20% of respiratory infections worldwide and are present in all continents <xref rid="bib0003" ref-type="bibr">[3]</xref>, <xref rid="bib0004" ref-type="bibr">[4]</xref>, <xref rid="bib0005" ref-type="bibr">[5]</xref>, <xref rid="bib0006" ref-type="bibr">[6]</xref>, <xref rid="bib0007" ref-type="bibr">[7]</xref>, <xref rid="bib0008" ref-type="bibr">[8]</xref>, <xref rid="bib0009" ref-type="bibr">[9]</xref>, <xref rid="bib0010" ref-type="bibr">[10]</xref>, <xref rid="bib0011" ref-type="bibr">[11]</xref>, <xref rid="bib0012" ref-type="bibr">[12]</xref>, <xref rid="bib0013" ref-type="bibr">[13]</xref>, <xref rid="bib0014" ref-type="bibr">[14]</xref> (<xref rid="tbl0001" ref-type="table">Table 1</xref>). Mortality is poorly assessed, but it is clear that there are chronic carriers as well as asymptomatic carriers. Studies have shown that there are as many asymptomatic carriers as symptomatic patients <xref rid="bib0003" ref-type="bibr">[3</xref>,<xref rid="bib0009" ref-type="bibr">9]</xref>. Three epidemic episodes of emerging coronaviruses have been reported. The first, severe acute respiratory syndrome (SARS) coronavirus, had very little impact on global morbidity and mortality, with more than 8000 recognized cases and 774 deaths <xref rid="bib0015" ref-type="bibr">[15</xref>,<xref rid="bib0016" ref-type="bibr">16]</xref>. The second, Middle East respiratory syndrome (MERS)-coronavirus, remained localized in Saudi Arabia, with a small epidemic of mainly nosocomial infections in South Korea <xref rid="bib0017" ref-type="bibr">[17]</xref>. MERS-coronavirus, like SARS-coronavirus, highlighted the major danger of nosocomial transmission to healthcare personnel, the health of whom is essential in these epidemics <xref rid="bib0018" ref-type="bibr">[18]</xref>. Finally, SARS-CoV-2, the novel coronavirus that appeared in December 2019, has expanded and has now affected more than 90 000 people worldwide <xref rid="bib0002" ref-type="bibr">[2</xref>,<xref rid="bib0019" ref-type="bibr">19</xref>,<xref rid="bib0020" ref-type="bibr">20]</xref>. At the time of writing, a significant number of cases had occurred in the Far East. It is incontestably contagious, as a quasi-experimental study on the <italic>Diamond Princess</italic> cruise ship showed that confinement of infected patients with uninfected patients resulted in rapid infection of the uninfected patients, leading to 700 additional cases on board <xref rid="bib0021" ref-type="bibr">[21]</xref>. However, coronaviruses in common circulation remain predominant because of their global distribution and their non-negligible mortality <xref rid="bib0014" ref-type="bibr">[14</xref>,<xref rid="bib0022" ref-type="bibr">22]</xref>. The aim of this study was to share the experience of a reference laboratory representing approximately 1% of serious and diagnosed respiratory infections, particularly seasonal, in France. This will allow the evaluation of the relative mortality of different human coronaviruses presented in hospitals in Marseille compared with that of SARS-CoV-2.<table-wrap position="float" id="tbl0001"><label>Table 1</label><caption><p>Studies that tested for coronavirus in patients with fever in various countries</p></caption><alt-text id="alt0001">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top">First author [reference number]</th><th valign="top">Country</th><th valign="top">Tested cases (<italic>n</italic>)</th><th valign="top">Diagnosis of coronavirus</th></tr></thead><tbody><tr><td valign="top">Trombetta <xref rid="bib0007" ref-type="bibr">[7]</xref></td><td valign="top">Brazil</td><td valign="top">775</td><td valign="top">7.6%</td></tr><tr><td valign="top">Zhang <xref rid="bib0010" ref-type="bibr">[10]</xref></td><td valign="top">Guangzou, China</td><td valign="top">13 048</td><td valign="top">244 (2.25%)</td></tr><tr><td valign="top">Zeng <xref rid="bib0011" ref-type="bibr">[11]</xref></td><td valign="top">Guangzou, China</td><td valign="top">11 399</td><td valign="top">489 (4.3%)</td></tr><tr><td valign="top">Killerby <xref rid="bib0014" ref-type="bibr">[14]</xref></td><td valign="top">USA</td><td valign="top">18 806</td><td valign="top">2.2%</td></tr><tr><td valign="top">Kiyuka <xref rid="bib0013" ref-type="bibr">[13]</xref></td><td valign="top">Kenya</td><td valign="top">5573</td><td valign="top">10.1%</td></tr><tr><td valign="top">Owusu <xref rid="bib0009" ref-type="bibr">[9]</xref></td><td valign="top">Ghana</td><td valign="top">593 cases</td><td valign="top">13.7%</td></tr><tr><td valign="top">Dube <xref rid="bib0001a" ref-type="bibr">[30]</xref></td><td valign="top">South Africa</td><td valign="top">620 controls<break></break>214 (tuberculosis)</td><td valign="top">10.5%<break></break>8%</td></tr><tr><td valign="top">Sipulwa <xref rid="bib0012" ref-type="bibr">[12]</xref></td><td valign="top">Kenya</td><td valign="top">417</td><td valign="top">8.4%</td></tr><tr><td valign="top">Subramoney <xref rid="bib0001b" ref-type="bibr">[31]</xref></td><td valign="top">South Africa</td><td valign="top">860</td><td valign="top">4.8%</td></tr><tr><td valign="top">Nunes <xref rid="bib0001c" ref-type="bibr">[32]</xref></td><td valign="top">South Africa</td><td valign="top">1026</td><td valign="top">15%</td></tr><tr><td valign="top">Le-Viet <xref rid="bib0003" ref-type="bibr">[3]</xref></td><td valign="top">Vietnam</td><td valign="top">378</td><td valign="top">4 (1.05%)</td></tr></tbody></table></table-wrap></p></sec><sec id="sec0002"><label>2</label><title>Materials and methods</title><p id="para0008">Assistance Publique-Hôpitaux de Marseille (AP-HM) covers all public hospitals in Marseille, including four university hospitals: La Timone Hospital, Conception Hospital, North Hospital and South Hospital; this corresponds to 3400 beds and 125 000 admissions each year <xref rid="bib0023" ref-type="bibr">[23]</xref>. The IHU Méditerranée Infection diagnostic laboratory tests all samples from AP-HM in which respiratory viruses are suspected. Molecular biology is used for diagnosis. The results are monitored by a weekly automated surveillance system in the diagnostic laboratory, coupled with a laboratory information system (Nexlabs) <xref rid="bib0023" ref-type="bibr">[23]</xref>. SARS-CoV-2 epidemiological data were obtained through an online platform gathering data from public agencies <xref rid="bib0024" ref-type="bibr">[24]</xref>. Statistical analyses were performed using BiostatGV software.</p></sec><sec id="sec0003"><label>3</label><title>Results</title><p id="para0009">In 2016, there were 594 000 deaths in France; 59.2% of these deaths occurred in a care establishment <xref rid="bib0025" ref-type="bibr">[25]</xref>. In the same year, AP-HM reported 2854 deaths. As such, it can be estimated that approximately 0.8% of deaths in care establishments in France occurred in AP-HM hospitals. This estimate provides an approximation of the number of people affected by a pathogen in France according to the number of people who died each year at AP-HM hospitals.</p><p id="para0010">From 1 January 2013 to 31 December 2019, 21 662 samples were tested by the IHU Méditerranée Infection diagnostic laboratory. Among these, 770 samples were positive for coronavirus, with eight deaths (mortality rate 1%). Among identified coronaviruses, 63 were identified as HKU1 (one death, mortality rate 1.6%), 74 were identified as NL63 (two deaths, mortality rate 2.7%), 92 were identified as E229 (one death, mortality rate 1.1%) and 160 were identified as OC43 (four deaths, mortality rate 2.5%). Three hundred and eighty-one coronaviruses, diagnosed before 2017, were not assigned to any of these four strains (<xref rid="tbl0002" ref-type="table">Table 2</xref>).<table-wrap position="float" id="tbl0002"><label>Table 2</label><caption><p>Results from Assistance Publique-Hôpitaux de Marseille (AP-HM) diagnostic laboratory</p></caption><alt-text id="alt0002">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top">Agent</th><th align="left" valign="top">Location</th><th valign="top">Confirmed cases (<italic>n</italic>)</th><th valign="top">Deaths (<italic>n</italic>)</th><th valign="top">Mortality rate (%)</th></tr></thead><tbody><tr><td valign="top">Coronavirus<xref rid="tb2fn1" ref-type="table-fn">a</xref></td><td align="left" rowspan="5" valign="top">AP-HM, Marseille, France</td><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr><tr><td valign="top">Coronavirus OC43</td><td valign="top">160</td><td valign="top">4</td><td valign="top">0.0250</td></tr><tr><td valign="top">Coronavirus NL63</td><td valign="top">74</td><td valign="top">2</td><td valign="top">0.0270</td></tr><tr><td valign="top">Coronavirus HKU1</td><td valign="top">63</td><td valign="top">1</td><td valign="top">0.0159</td></tr><tr><td valign="top">Coronavirus E229</td><td valign="top">92</td><td valign="top">1</td><td valign="top">0.0109</td></tr><tr><td valign="top">Coronavirus<xref rid="tb2fn2" ref-type="table-fn">b</xref></td><td align="left" rowspan="5" valign="top">AP-HM, Marseille, France</td><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr><tr><td valign="top">Coronavirus OC43</td><td valign="top">77</td><td valign="top">1</td><td valign="top">0.0130</td></tr><tr><td valign="top">Coronavirus NL63</td><td valign="top">146</td><td valign="top">0</td><td valign="top">0</td></tr><tr><td valign="top">Coronavirus HKU1</td><td valign="top">277</td><td valign="top">1</td><td valign="top">0.0036</td></tr><tr><td valign="top">Coronavirus E229</td><td valign="top">43</td><td valign="top">0</td><td valign="top">0</td></tr></tbody></table><table-wrap-foot><fn id="tb2fn1"><label>a</label><p id="notep0001">From 1 January 2013 to 31 December 2019.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb2fn2"><label>b</label><p id="notep0002">From 1 January 2020 to 2 March 2020.</p></fn></table-wrap-foot></table-wrap></p><p id="para0011">Systematic testing (molecular biology) for SARS-CoV-2 was performed from 1 January 2020 to 2 March 2020. In total, 7059 samples from patients presenting with infectious symptoms were tested by the IHU Méditerranée Infection diagnostic laboratory. Among them, 543 samples were positive for coronaviruses, with two deaths (mortality rate 0.36%): 277 samples were HKU1, 146 samples were NL63, 77 samples were OC43 and 43 samples were 229E. No cases of SARS-CoV-2 were identified among these samples. Of the two deaths, one patient had OC43 (mortality rate 1.3%) and one patient had HKU1 (mortality rate 0.36%). There were no deaths from NL63 or E229 during this period.</p><p id="para0012">Over the same period, IHU Méditerranée Infection was the regional centre for detection of the novel coronavirus SARS-CoV-2. At the time of writing, 596 analyses have been performed on suspected cases since the emergence of the novel pathogen, from which four cases of SARS-CoV-2 have been identified. In addition, 337 French nationals returning from Hubei Province have been tested twice, and all were negative for SARS-CoV-2.</p><p id="para0013">By 2 March 2020, a total of 90 307 patients have tested positive for SARS-CoV-2 worldwide, with 3086 deaths (mortality rate 3.4%). Among the Organisation for Economic Co-operation and Development (OECD) countries, 7476 patients have tested positive for SARS-CoV-2, with 96 deaths (mortality rate 1.3%) (<xref rid="tbl0003" ref-type="table">Table 3</xref>). In France, 191 people have tested positive for SARS-CoV-2, with three deaths (mortality rate 1.6%).<table-wrap position="float" id="tbl0003"><label>Table 3</label><caption><p>SARS-CoV-2 international epidemiological situation (Organisation for Economic Co-operation and Development countries), 3 March 2020</p></caption><alt-text id="alt0003">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top">Countries</th><th valign="top">Confirmed cases (<italic>n</italic>)</th><th valign="top">Deaths (<italic>n</italic>)</th><th valign="top">Mortality rate (%)</th></tr></thead><tbody><tr><td valign="top">Germany</td><td valign="top">157</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Australia</td><td valign="top">30</td><td valign="top">1</td><td valign="top">3.3</td></tr><tr><td valign="top">Austria</td><td valign="top">18</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Belgium</td><td valign="top">8</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Canada</td><td valign="top">24</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">South Korea</td><td valign="top">4335</td><td valign="top">28</td><td valign="top">0.6</td></tr><tr><td valign="top">Denmark</td><td valign="top">4</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Spain</td><td valign="top">123</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Estonia</td><td valign="top">1</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">USA</td><td valign="top">100</td><td valign="top">6</td><td valign="top">6.0</td></tr><tr><td valign="top">Finland</td><td valign="top">7</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">France</td><td valign="top">191</td><td valign="top">3</td><td valign="top">1.6</td></tr><tr><td valign="top">Greece</td><td valign="top">7</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Ireland</td><td valign="top">1</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Iceland</td><td valign="top">3</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Israel</td><td valign="top">10</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Italy</td><td valign="top">2036</td><td valign="top">52</td><td valign="top">2.6</td></tr><tr><td valign="top">Japan</td><td valign="top">274</td><td valign="top">6</td><td valign="top">2.2</td></tr><tr><td valign="top">Latvia</td><td valign="top">1</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Lithuania</td><td valign="top">1</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Luxembourg</td><td valign="top">1</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Mexico</td><td valign="top">5</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Norway</td><td valign="top">25</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">New Zealand</td><td valign="top">1</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Netherlands</td><td valign="top">18</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Portugal</td><td valign="top">2</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Sweden</td><td valign="top">15</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Switzerland</td><td valign="top">38</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">UK</td><td valign="top">40</td><td valign="top">0</td><td valign="top">0.0</td></tr><tr><td valign="top">Total</td><td valign="top">7476</td><td valign="top">96</td><td valign="top">1.3</td></tr></tbody></table></table-wrap></p><p id="para0014">This study compared the mortality rate of SARS-CoV-2 in OECD countries (1.3%) with the mortality rate of common coronaviruses identified in AP-HM patients (0.8%) from 1 January 2013 to 2 March 2020. Chi-squared test was performed, and the <italic>P</italic>-value was 0.11 (not significant).</p></sec><sec id="sec0004"><label>4</label><title>Discussion</title><p id="para0015">This study found that the mortality rate of common coronavirus infections is 0.8% in France. In comparison, the mortality rate of SARS-CoV-2 in European or American developed countries of a comparable economic level is 1.3% (<xref rid="tbl0003" ref-type="table">Table 3</xref>). If the extrapolation of deaths in AP-HM hospitals is correct, in metropolitan France, this would represent 543/0.8 * 100 = 67 875 cases of patients hospitalized with a respiratory infection with common coronaviruses in 2 months, which is almost as many cases as for SARS-CoV-2 worldwide. In fact, mortality from respiratory infections is extremely dependent on the quality of care and access to care, and severe forms have a better prognosis in countries with superior medical infrastructures. Under these conditions, there does not seem to be a significant difference between the mortality rate of SARS-CoV-2 in OECD countries and that of common coronaviruses (χ<sup>2</sup> test, <italic>P</italic>=0.11). Of course, the major flaw in this study is that the percentage of deaths attributable to the virus is not determined, but this is the case for all studies reporting respiratory virus infections, including SARS-CoV-2. Indeed, viral infections are ecosystem infections where the outcome depends on the inoculums and the surrounding microbiota <xref rid="bib0026" ref-type="bibr">[26]</xref>. Thus, certain bacteria seem to be associated with symptomatic manifestations, such as <italic>Streptococcus pneumoniae, Haemophilus influenzae</italic> and <italic>Staphylococcus aureus</italic>, which are known to cause an excess of mortality due to secondary infection. Finally, seasonality, geographic location, heat and humidity are co-factors, as are age, gender and underlying pathologies. Under these conditions, and all other things being equal, SARS-CoV-2 infection cannot be described as being statistically more severe than infection with other coronaviruses in common circulation.</p><p id="para0016">Finally, in OECD countries, SARS-CoV-2 does not seem to be deadlier than other circulating viruses. In addition to coronaviruses, there are 16 endemic viruses in common circulation in developed countries (adenovirus, bocavirus, cytomegalovirus, enterovirus, influenza A H1N1 virus, influenza A H3N2 virus, influenza B virus, metapneumovirus, parainfluenzae virus 1, parainfluenzae virus 2, parainfluenzae virus 3, parainfluenzae virus 4, parechovirus, picornavirus, rhinovirus, syncytial respiratory virus), and 2.6 million deaths from respiratory infections (excluding tuberculosis) per year have been noted in recent years worldwide <xref rid="bib0027" ref-type="bibr">[27]</xref>. There is little chance that the emergence of SARS-CoV-2 could change this statistic significantly. Fear could have a larger impact than the virus itself; a case of suicide motivated by the fear of SARS-COV-2 has been reported in India <xref rid="bib0028" ref-type="bibr">[28]</xref>.</p><p id="para0017">In addition, coronaviruses that have rarely been tested systematically around the world may persist in the pharynx of asymptomatic people, representing a potential source of population immunity <xref rid="bib0029" ref-type="bibr">[29]</xref>. Furthermore, it should be noted that systematic studies of other coronaviruses (but not yet for SARS-CoV-2) have found that the percentage of asymptomatic carriers is equal to or even higher than the percentage of symptomatic patients. The same data for SARS-CoV-2 may soon be available, which will further reduce the relative risk associated with this specific pathology.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name><surname>To</surname><given-names>K.K.</given-names></name><name><surname>Hung</surname><given-names>I.F.</given-names></name><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>From SARS coronavirus to novel animal and human coronaviruses</article-title><source>J Thorac Dis</source><volume>5</volume><issue>Suppl. 2</issue><year>2013</year><fpage>S103</fpage><lpage>S108</lpage><pub-id pub-id-type="pmid">23977429</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>McGoogan</surname><given-names>J.M.</given-names></name></person-group><article-title>Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention [published online ahead of print, 24 February 2020]</article-title><source>JAMA</source><year>2020</year></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name><surname>Le-Viet</surname><given-names>N.</given-names></name><name><surname>Le</surname><given-names>V.N.</given-names></name><name><surname>Chung</surname><given-names>H.</given-names></name></person-group><article-title>Prospective case–control analysis of the aetiologies of acute undifferentiated fever in Vietnam</article-title><source>Emerg Microbes Infect</source><volume>8</volume><year>2019</year><fpage>339</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">30866787</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name><surname>Hand</surname><given-names>J.</given-names></name><name><surname>Rose</surname><given-names>E.B.</given-names></name><name><surname>Salinas</surname><given-names>A.</given-names></name></person-group><article-title>Severe respiratory illness outbreak associated with human coronavirus NL63 in a long-term care facility</article-title><source>Emerg Infect Dis</source><volume>24</volume><year>2018</year><fpage>1964</fpage><lpage>1966</lpage><pub-id pub-id-type="pmid">30226169</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Vandroux</surname><given-names>D.</given-names></name><name><surname>Allou</surname><given-names>N.</given-names></name><name><surname>Jabot</surname><given-names>J.</given-names></name></person-group><article-title>Intensive care admission for coronavirus OC43 respiratory tract infections</article-title><source>Med Mal Infect</source><volume>48</volume><year>2018</year><fpage>141</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">29402475</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name><surname>Kanwar</surname><given-names>A.</given-names></name><name><surname>Selvaraju</surname><given-names>S.</given-names></name><name><surname>Esper</surname><given-names>F.</given-names></name></person-group><article-title>Human coronavirus-HKU1 infection among adults in Cleveland, Ohio</article-title><source>Open Forum Infect Dis</source><volume>4</volume><year>2017</year><comment>ofx052</comment></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name><surname>Trombetta</surname><given-names>H.</given-names></name><name><surname>Faggion</surname><given-names>H.Z.</given-names></name><name><surname>Leotte</surname><given-names>J.</given-names></name><name><surname>Nogueira</surname><given-names>M.B.</given-names></name><name><surname>Vidal</surname><given-names>L.R.</given-names></name><name><surname>Raboni</surname><given-names>S.M.</given-names></name></person-group><article-title>Human coronavirus and severe acute respiratory infection in Southern Brazil</article-title><source>Pathog Glob Health</source><volume>110</volume><year>2016</year><fpage>113</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">27195607</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>S.K.</given-names></name><name><surname>Woo</surname><given-names>P.C.</given-names></name><name><surname>Yip</surname><given-names>C.C.</given-names></name></person-group><article-title>Coronavirus HKU1 and other coronavirus infections in Hong Kong</article-title><source>J Clin Microbiol</source><volume>44</volume><year>2006</year><fpage>2063</fpage><lpage>2071</lpage><pub-id pub-id-type="pmid">16757599</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name><surname>Owusu</surname><given-names>M.</given-names></name><name><surname>Annan</surname><given-names>A.</given-names></name><name><surname>Corman</surname><given-names>V.M.</given-names></name></person-group><article-title>Human coronaviruses associated with upper respiratory tract infections in three rural areas of Ghana</article-title><source>PLoS One</source><volume>9</volume><year>2014</year><fpage>e99782</fpage><pub-id pub-id-type="pmid">25080241</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.F.</given-names></name><name><surname>Tuo</surname><given-names>J.L.</given-names></name><name><surname>Huang</surname><given-names>X.B.</given-names></name></person-group><article-title>Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010–2015 in Guangzhou</article-title><source>PLoS One</source><volume>13</volume><year>2018</year><object-id pub-id-type="publisher-id">e0191789</object-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Z.Q.</given-names></name><name><surname>Chen</surname><given-names>D.H.</given-names></name><name><surname>Tan</surname><given-names>W.P.</given-names></name></person-group><article-title>Epidemiology and clinical characteristics of human coronaviruses OC43, 229E, NL63, and HKU1: a study of hospitalized children with acute respiratory tract infection in Guangzhou, China</article-title><source>Eur J Clin Microbiol Infect Dis</source><volume>37</volume><year>2018</year><fpage>363</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">29214503</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name><surname>Sipulwa</surname><given-names>L.A.</given-names></name><name><surname>Ongus</surname><given-names>J.R.</given-names></name><name><surname>Coldren</surname><given-names>R.L.</given-names></name><name><surname>Bulimo</surname><given-names>W.D.</given-names></name></person-group><article-title>Molecular characterization of human coronaviruses and their circulation dynamics in Kenya, 2009–2012</article-title><source>Virol J</source><volume>13</volume><year>2016</year><fpage>18</fpage><pub-id pub-id-type="pmid">26833249</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name><surname>Kiyuka</surname><given-names>P.K.</given-names></name><name><surname>Agoti</surname><given-names>C.N.</given-names></name><name><surname>Munywoki</surname><given-names>P.K.</given-names></name></person-group><article-title>Human coronavirus NL63 molecular epidemiology and evolutionary patterns in rural coastal Kenya</article-title><source>J Infect Dis</source><volume>217</volume><year>2018</year><fpage>1728</fpage><lpage>1739</lpage><pub-id pub-id-type="pmid">29741740</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name><surname>Killerby</surname><given-names>M.E.</given-names></name><name><surname>Biggs</surname><given-names>H.M.</given-names></name><name><surname>Haynes</surname><given-names>A.</given-names></name></person-group><article-title>Human coronavirus circulation in the United States 2014–2017</article-title><source>J Clin Virol</source><volume>101</volume><year>2018</year><fpage>52</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">29427907</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Stöhr</surname><given-names>K.</given-names></name></person-group><article-title>The severe acute respiratory syndrome</article-title><source>N Engl J Med</source><volume>349</volume><year>2003</year><fpage>2431</fpage><lpage>2441</lpage><pub-id pub-id-type="pmid">14681510</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E.</given-names></name><name><surname>van Doremalen</surname><given-names>N.</given-names></name><name><surname>Falzarano</surname><given-names>D.</given-names></name><name><surname>Munster</surname><given-names>V.J.</given-names></name></person-group><article-title>SARS and MERS: recent insights into emerging coronaviruses</article-title><source>Nat Rev Microbiol</source><volume>14</volume><year>2016</year><fpage>523</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">27344959</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name><surname>Zaki</surname><given-names>A.M.</given-names></name><name><surname>van Boheemen</surname><given-names>S.</given-names></name><name><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name></person-group><article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia [published correction appears in N Engl J Med 2013;369:394]</article-title><source>N Engl J Med</source><volume>367</volume><year>2012</year><fpage>1814</fpage><lpage>1820</lpage><pub-id pub-id-type="pmid">23075143</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>Azhar</surname><given-names>E.I.</given-names></name><name><surname>Kim</surname><given-names>Y.J.</given-names></name><name><surname>Memish</surname><given-names>Z.A.</given-names></name><name><surname>Oh</surname><given-names>M.D.</given-names></name><name><surname>Zumla</surname><given-names>A.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission</article-title><source>Lancet Infect Dis</source><volume>18</volume><year>2018</year><fpage>e217</fpage><lpage>e227</lpage><pub-id pub-id-type="pmid">29680581</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="book" id="sbref0019"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><chapter-title>Coronavirus disease (COVID-19) outbreak</chapter-title><year>2020</year><publisher-name>WHO</publisher-name><publisher-loc>Geneva</publisher-loc><comment>Available at:</comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019" id="interref0001">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</ext-link><comment>[accessed 4 March 2020]</comment></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><collab>Novel Coronavirus Pneumonia Emergency Response Epidemiology Team</collab></person-group><article-title>The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) in China</article-title><source>Zhonghua Liu Xing Bing Xue Za Zhi</source><volume>41</volume><year>2020</year><fpage>145</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">32064853</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name><surname>Rocklöv</surname><given-names>J.</given-names></name><name><surname>Sjödin</surname><given-names>H.</given-names></name><name><surname>Wilder-Smith</surname><given-names>A.</given-names></name></person-group><article-title>COVID-19 outbreak on the <italic>Diamond Princess</italic> cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures [published online ahead of print, 28 February 2020]</article-title><source>J Travel Med</source><year>2020</year><comment>taaa030</comment></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name><surname>Gagneur</surname><given-names>A.</given-names></name><name><surname>Vallet</surname><given-names>S.</given-names></name><name><surname>Talbot</surname><given-names>P.J.</given-names></name></person-group><article-title>Outbreaks of human coronavirus in a pediatric and neonatal intensive care unit</article-title><source>Eur J Pediatr</source><volume>167</volume><year>2008</year><fpage>1427</fpage><lpage>1434</lpage><pub-id pub-id-type="pmid">18335238</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name><surname>Abat</surname><given-names>C.</given-names></name><name><surname>Chaudet</surname><given-names>H.</given-names></name><name><surname>Colson</surname><given-names>P.</given-names></name><name><surname>Rolain</surname><given-names>J.M.</given-names></name><name><surname>Raoult</surname><given-names>D.</given-names></name></person-group><article-title>Real-time microbiology laboratory surveillance system to detect abnormal events and emerging infections, Marseille, France</article-title><source>Emerg Infect Dis</source><volume>21</volume><year>2015</year><fpage>1302</fpage><lpage>1310</lpage><pub-id pub-id-type="pmid">26196165</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><mixed-citation publication-type="other" id="othref0001"><ext-link ext-link-type="uri" xlink:href="https://docs.google.com/spreadsheets/d/1f3LGuqwzegr7ZdGlzPOCDAyFk8RTaLTmMLF_K_5EVCc/edit#gid=783518927" id="interref0002">https://docs.google.com/spreadsheets/d/1f3LGuqwzegr7ZdGlzPOCDAyFk8RTaLTmMLF_K_5EVCc/edit#gid=783518927</ext-link>[accessed 3 March 2020].</mixed-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0024"><article-title>Institut national de la statistique et des études économiques. 594 000 personnes décédées en France en 2016, pour un quart d'entre elles à leur domicile</article-title><source>INSEE FOCUS</source><year>2017</year><comment>N°95Available at:</comment><ext-link ext-link-type="uri" xlink:href="https://www.insee.fr/fr/statistiques/3134763" id="interref0003">https://www.insee.fr/fr/statistiques/3134763</ext-link><comment>[accessed 3 March 2020]</comment></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Edouard</surname><given-names>S.</given-names></name><name><surname>Million</surname><given-names>M.</given-names></name><name><surname>Bachar</surname><given-names>D.</given-names></name></person-group><article-title>The nasopharyngeal microbiota in patients with viral respiratory tract infections is enriched in bacterial pathogens</article-title><source>Eur J Clin Microbiol Infect Dis</source><volume>37</volume><year>2018</year><fpage>1725</fpage><lpage>1733</lpage><pub-id pub-id-type="pmid">30033505</pub-id></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><collab>GBD 2017 Mortality Collaborators</collab></person-group><article-title>Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 [published correction appears in Lancet 2019;393:e44]</article-title><source>Lancet</source><volume>392</volume><year>2018</year><fpage>1684</fpage><lpage>1735</lpage><pub-id pub-id-type="pmid">30496102</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name><surname>Goyal</surname><given-names>K.</given-names></name><name><surname>Chauhan</surname><given-names>P.</given-names></name><name><surname>Chhikara</surname><given-names>K.</given-names></name><name><surname>Gupta</surname><given-names>P.</given-names></name><name><surname>Singh</surname><given-names>M.P.</given-names></name></person-group><article-title>Fear of COVID 2019: first suicidal case in India!</article-title><source>Asian J Psychiatr</source><volume>49</volume><year>2020</year><object-id pub-id-type="publisher-id">101989</object-id></element-citation></ref><ref id="bib0029"><label>29</label><mixed-citation publication-type="other" id="othref0002">Raoult D, Zumla A, Locatelli F, et al. Coronavirus infections: epidemiological, clinical and immunological features and hypotheses. Cell Stress, in press [published online ahead of print, 24 February 2020].</mixed-citation></ref><ref id="bib0001a"><label>30</label><element-citation publication-type="journal" id="sbref0001aa"><person-group person-group-type="author"><name><surname>Dube</surname><given-names>F.S.</given-names></name><name><surname>Kaba</surname><given-names>M.</given-names></name><name><surname>Robberts</surname><given-names>F.J.</given-names></name></person-group><article-title>Respiratory microbes present in the nasopharynx of children hospitalised with suspected pulmonary tuberculosis in Cape Town, South Africa</article-title><source>BMC Infect Dis.</source><volume>16</volume><issue>1</issue><year>2016</year><fpage>597</fpage><pub-id pub-id-type="pmid">27776489</pub-id></element-citation></ref><ref id="bib0001b"><label>31</label><element-citation publication-type="journal" id="sbref0001at"><person-group person-group-type="author"><name><surname>K.</surname><given-names>Subramoney</given-names></name><name><surname>O.</surname><given-names>Hellferscee</given-names></name><name><surname>M.</surname><given-names>Pretorius</given-names></name></person-group><article-title>Human bocavirus, coronavirus, and polyomavirus detected among patients hospitalised with severe acute respiratory illness in South Africa, 2012 to 2013</article-title><source>Health Sci Rep.</source><volume>1</volume><issue>8</issue><year>2018</year><fpage>e59</fpage><pub-id pub-id-type="pmid">30623094</pub-id></element-citation></ref><ref id="bib0001c"><label>32</label><element-citation publication-type="journal" id="sbref0001pa"><person-group person-group-type="author"><name><surname>Nunes</surname><given-names>M.C.</given-names></name><name><surname>Kuschner</surname><given-names>Z.</given-names></name><name><surname>Rabede</surname><given-names>Z.</given-names></name></person-group><article-title>Clinical epidemiology of bocavirus, rhinovirus, two polyomaviruses and four coronaviruses in HIV-infected and HIV-uninfected South African children</article-title><source>PLoS One</source><volume>9</volume><issue>2</issue><year>2014</year><fpage>e86448</fpage><pub-id pub-id-type="pmid">24498274</pub-id></element-citation></ref></ref-list><ack id="ack0001"><title>Declarations</title><p><bold>Funding:</bold> This work was supported by the French Government under the ‘Investments for the Future’ programme managed by the National Agency for Research, Méditerranée-Infection 10-IAHU-03.</p><p><bold>Competing interests</bold>: None declared.</p><p><bold>Ethical approval:</bold> Not applicable. Testing of repatriates was approved by the ethical board of the Committee for the Protection of Persons (CPP Ile de France VI, 6 February 2020).</p></ack></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001066 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001066 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7102597
|texte= SARS-CoV-2: fear versus data
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:32201354" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |